Meeting Coverage:

American Academy of Ophthalmology

AAO: 2024

Extension Data for High-Dose Aflibercept

Show Description +

Dr. Do shares key results from the PHOTON extension study, which switched patients with diabetic macular edema who were treated with 2 mg aflibercept (Eylea, Regeneron) in PHOTON to 8 mg aflibercept (Eylea HD, Regeneron).

Posted: 10/22/2024

Up Next

The Promise of a Wnt Agonist

Charles C. Wykoff, MD, PhD


The Risk of PVR Revealed

Mathew W. MacCumber, MD, PHD

The 2024 Charles L Schepens MD Lecture

Steve Charles, MD, FACS, FICS

Fellow-Eye Dosing of ABBV-RGX-314 Gene Therapy

Arshad M. Khanani, MD, MA, FASRS

Glaucoma Lasers: What’s New?

Sarah Van Tassel, MD

Visual Field Progression in the LiGHT Trial

Gus Gazzard, MA(Cantab), MD, MBBChir, FRCOphth

Updates on a Novel Oral Therapy for DME

Joel A. Pearlman, MD, PhD

Extension Data for High-Dose Aflibercept

Dr. Do shares key results from the PHOTON extension study, which switched patients with diabetic macular edema who were treated with 2 mg aflibercept (Eylea, Regeneron) in PHOTON to 8 mg aflibercept (Eylea HD, Regeneron).

Posted: 10/22/2024


Please log in to leave a comment.

More From AAO: 2024 Coverage